STAT+: Biotech raises $42 million to run Huntington’s disease trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Latus Bio secured $42 million in funding to start its first clinical trials.
- Beverly Davidson – chief scientific strategy officer at Children’s Hospital of Philadelphia – co‑founded Latus Bio.
- Latus Bio will launch a gene‑therapy trial for Huntington’s disease this year, aiming to avoid setbacks that stalled a rival.
- Latus Bio also plans to deliver early clinical data for its CLN2 disease therapy by the end of the year.
Why it matters: Latus Bio and its investors gain $42 million to advance Huntington’s disease therapy, while patients await a new treatment; the trial will add momentum to gene‑therapy development for neurodegenerative disorders.
Ask SkimNews
